Mirum Pharmaceuticals (MIRM) said Thursday that its partner Takeda Pharmaceutical (TAK) has received clearance by Japan's Ministry of Health, Labour, and Welfare for Livmarli oral solution to treat cholestatic pruritus in people with Alagille syndrome and progressive familial intrahepatic cholestasis.
Mirum said the company and Takeda signed an exclusive licensing deal in September 2021 for the development and commercialization of Livmarli for rare cholestatic pediatric liver diseases in Japan.
Under the terms of the deal, Mirum is eligible to get a percentage of Takeda's annual net sales, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。